World Neuroscience Innovation Forum to be Held at London’s Francis Crick Institute
6.3.2017 08:00 | Business Wire
Partners HealthCare, a Boston-based hospital system that includes Brigham and Women’s Hospital and Massachusetts General Hospital, and whose faculty teach at Harvard Medical School, today announced the first World Neuroscience Innovation Forum, which will bring together senior corporate executives, top clinicians, venture investors, and leading researchers from the U.S. and Europe to battle diseases that afflict one in six people around the world. The Forum will take place at the Francis Crick Institute in London on March 27, 2017.
“Neurodegenerative and related diseases are among the greatest challenges confronting contemporary society and their enormous growth represent a potential economic cataclysm. This global gathering of some of the world’s top neuroscience leaders will catalyze new connections, conversations and thinking around these unprecedented challenges,” said Rudolph E. Tanzi, Ph.D., Vice-Chair of Neurology, Director of Genetics and Aging Research Unit, Massachusetts General Hospital, and Joseph P. and Rose F. Kennedy Professor of Neurology, Harvard Medical School.
The Forum will launch the Springboard Challenge, an award competition that will seed new international, multi-sector neuroscience teams dedicated to the development of disruptive approaches to improve therapeutics and diagnostics to treat neurodegenerative (NDD) or neuroinflammatory (NID) diseases. The Challenge will offer three awards of $50,000 each and mentorship support from leading UK and US venture capitalists. The awards are intended to fund team meetings, logistics, and strategic planning efforts for the proposed solution. Collaborations enabled by the awards will seek multi-year support from Forum industry sponsors, governments, investors, foundations and other organizations. Award selections will be made in the summer of 2017.
“Alzheimer’s and other neurological diseases such as epilepsy, multiple sclerosis and Parkinson’s afflict one in six people around the world and a truly global effort is needed to combat them. The World Forum will support and enhance that effort by inspiring the kind of interactions and collaborations that can lead to life-changing products and therapies,” said Anne Klibanski, M.D., Chief Academic Officer for Partners HealthCare and the Forum’s organizer.
The Forum will feature highly interactive panel discussions on topics ranging from investment priorities to therapies to the impact of neurodegeneration on the health care system, as well as keynote sessions with Biogen and Eli Lilly.
“The complexity of discovering treatment for neurodegenerative diseases requires an innovative and collaborative approach in order to advance the knowledge we have about these conditions,” said Michael Ehlers, M.D., Ph.D., Executive Vice President, Research and Development, Biogen. “Biogen is committed to researching and developing treatments for neurodegenerative diseases like Alzheimer’s and Parkinson’s disease. Through our support of events like the World Neuroscience Innovation Forum, we hope to accelerate the discovery of new medicines for the people who need them.”
“Lilly is committed to battling neurodegenerative diseases,” said John C. Lechleiter, Chairman of the Board, Lilly. “The World Forum will be an important milestone in the efforts to unravel the complexity of these diseases and act on them to help millions of patients around the world.”
Sponsors of the Forum include Biogen, Lilly, GSK, Pfizer, the Francis Crick Institute, the High Lantern Group, Imperial College Health Partners, Janssen Neuroscience and MedCity.
For more information or to register, please go to http://neuroscienceinnovationforum.org/.
Partners HealthCare is a Boston-based integrated health system founded by Brigham and Women’s Hospital and Massachusetts General Hospital. In addition to its two academic medical centers, the Partners system includes community and specialty hospitals, a managed care organization, community health centers, a physician network, home health and long-term care services, and other health-related entities. Partners is the largest academic research organization in the Unites States and a principal teaching affiliate of Harvard Medical School. Partners HealthCare is a non-profit organization.
The Francis Crick Institute is a unique partnership between the Medical Research Council (MRC), Cancer Research UK, Wellcome, UCL (University College London), Imperial College London and King's College London.
Rich Copp, 617-278-1031
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
The Valence Group Issues Fairness Opinion to SK Capital in Connection with Archroma18.8.2017 13:30 | Pressemelding
The Valence Group has provided a fairness opinion to SK Capital Partners, LP in connection with its recapitalization of Archroma, including investments made by various affiliates of SK Capital. Terms of the transaction were not disclosed. About SK Capital SK Capital is a private investment firm focused on the specialty materials, chemicals and pharmaceutical sectors. The firm builds strong and growing businesses that generate substantial long-term value for its investors. SK Capital utilizes its industry, operating and investment experience to identify opportunities to transform businesses into higher performing companies with improved strategic positioning, growth, profitability and risk profiles. The firm currently has approximately $1.9 billion of assets under management and its portfolio companies generate revenues of over $5.0 billion annually and employ approximat
Biker Summer 2017 campaign: What’s happening during Biker Summer 2017? Moto-tyres.co.uk is giving away exciting prizes!18.8.2017 09:22 | Pressemelding
Whether it’s a short weekend break or a long-distance tour – once again this year Moto-tyres.co.uk is asking bikers from 10 countries about their dream destinations and longest journeys as part of its “Biker Summer 2017” campaign. To ensure than nothing gets in the way of your next tour, the two-wheeler tyre store from Delticom, Europe’s leading online tyre dealer, is entering anyone who completes the survey before 30 September 2017 into a prize draw to win some great biking accessories. Simply answer three short questions about your plans for bike tours this year (don’t forget to provide your name and email address), and with a bit of luck, you might win one of these great prizes. Up for grabs are a GARMIN motorbike GPS system, a GoPro camera with helmet bracket and five 200-Pound vouchers for new motorbike tyres from the online store – thanks to the product range at Moto-tyres.co.uk, eve
Lenovo Continues to Gain Momentum in First Quarter FY 2017/1818.8.2017 00:04 | Pressemelding
Behind the strength of its 3-wave strategy, Lenovo’s business transformation continued to gain traction during the first quarter, delivering solid profitability in its core PC and smart devices business, and revenue and profit improvements in targeted growth areas, including the data center and mobile businesses. Fueled by new investments in people and products, Lenovo’s Data Center Group (DCG) introduced the most comprehensive product lineup in its history, with the new ThinkSystem and ThinkAgile portfolio, and continued to build out its end-to-end sales organization. Similarly, Lenovo’s Mobile Business Group launched significant new products led by the Moto Z2 Force, available now on all major U.S. carriers, and ramped up its branding efforts worldwide. “In the first quarter this fiscal year, we had stable performance as we executed our 3-wave strategy with commitment. We
Spirent Tests Wi-Fi Network Performance with O2 at the Coca-Cola London Eye17.8.2017 15:57 | Pressemelding
Spirent Communications plc (LSE:SPT), today announced its Landslide E10 network test platform has been used with O2 to validate the Wi-Fi network performance and capacity at the Coca-Cola London Eye, before the launch of a new smartphone application last month. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170817005758/en/ Spirent Landslide E10 helped O2 validate Wi-Fi performance and capacity at the Coca-Cola London Eye, before the launch of a new smartphone application last month. (Photo: Busines Wire) Merlin Entertainments plc, operator of the London Eye, wanted to measure its Wi-Fi network performance, to ensure its infrastructure could provide an excellent experience for users of the new app, which puts increased demands on the Wi-Fi network. “The London Eye is a global attractio
Watch BizWireTV: A Camera You Can Wear and Krispy Kreme’s Famous Donuts Get Eclipsed with Chocolate17.8.2017 12:08 | Pressemelding
On BizWireTV, catch some Quick Biz Hits and see the latest in Star Power. Also see what’s happening in the startup world with the Accelerator Report, featuring the VC Watch and this week’s Startup Standout. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170817005305/en/ BizWireTV is hosted by Jordyn Rolling (Photo: Business Wire Now you can watch BizWireTV, and the latest breakthroughs in tech from the biggest brands, on any screen you want by downloading the new app through the Apple TV and iPhone App Store and Google Play for Android devices. Top of the Wire Introducing FrontRow: the camera re-invented. Watch BizWireTV to see more disruptors as well as the top 5 trending stories of the week! A core c
PsiOxus Therapeutics Announce Two New Board Appointments: New Board Appointments Strengthen Company’s US Presence17.8.2017 07:00 | Pressemelding
PsiOxus Therapeutics, Ltd. (PsiOxus) today announced the appointment of Charles Rowland and Duncan Higgons to the Board of Directors as part of an ongoing drive to expand in the US. Charles Rowland was most recently the President and Chief Executive Officer (CEO) of Aurinia Pharmaceuticals, a clinical stage pharmaceutical company focused on the global lupus nephritis market. Prior to this, he served as the Vice President and Chief Financial Officer (CFO) of ViroPharma, during which time the company grew into a global biopharmaceutical business with $500 million in annual revenues until it was acquired by Shire plc for $4.2 billion. Before joining ViroPharma, Mr. Rowland was executive Vice President, CFO, and interim co-CEO, for Endo Pharmaceuticals. In his earlier career, Charles held finance and operational positions at Biovail Pharmaceuticals, Breakaway Technologies, Pharmacia
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom